Skip to content

Community-engaged Approaches to Testing in Community and Healthcare Settings for Underserved Populations

Community-engaged Approaches to Testing in Community and Healthcare Settings for Underserved Populations

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04870307
Acronym
CATCH-UP
Enrollment
323
Registered
2021-05-03
Start date
2020-09-30
Completion date
2023-06-30
Last updated
2025-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Keywords

COVID-19, RADx-UP, Health Services Research, Implementation Science, Evidence-based practice, Social determinants of health

Brief summary

The pandemic caused by the novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has resulted in substantial global morbidity and mortality including in Oklahoma and caused unprecedented interruptions in nearly all aspects of our lives. The population of the state of Oklahoma is at particular risk to SARS-CoV-2 due to its large rural population, strained healthcare system, and poor overall health. The Community-Engaged Approaches to Testing in Community and Healthcare Settings for Underserved Populations (CATCH-UP) program will involve both practice-based and community-based approaches to maximize the reach of the Rapid Acceleration of Diagnostics - Underserved Populations (RADx-UP) consortium, broaden the potential perspectives that could be captured, and compare the effectiveness of strategies. The interventions will be pragmatic to allow CATCH-UP to respond to changing attitudes, barriers, and environments as the pandemic progresses as well as expected technology developments to produce more effective viral testing that can provide rapid results to patients. The investigators will assist 50 small primary care practices to implement guidelines-based testing and patient education about Coronavirus Disease 2019 (COVID-19) and risk mitigation strategies. The project's community-based approach is designed to rapidly respond to community testing needs by deploying mobile testing sites that will provide operational support to increase the efficiency and the existing capacity for state-wide testing by Oklahoma's public health authorities. Together, the investigators estimate that the CATCH-UP program will result in at least 105,000 SARS-CoV-2 tests performed during the first year of implementation. A comprehensive, ongoing evaluation will be performed to analyze patient and provider attitudes, barriers and facilitators of viral testing, identified health disparities caused by COVID-19, effectiveness of the intervention in both settings, and to allow robust collaboration with other RADx-UP consortium sites.

Detailed description

The broad RADx-UP initiative aims to understand the factors associated with COVID-19 morbidity and mortality disparities and to lay the foundation to reduce disparities for underserved and vulnerable populations disproportionately affected by the pandemic through efforts to increase access and effectiveness of diagnostic methods. The approach used in this project will leverage the investigators' experiences in designing and implementing evidence-based interventions in primary care settings, partnerships with Native American and Latino communities, investments in the development of community- driven and responsive organizations developed primarily in rural counties, and the capacity and needs of Oklahoma's government testing and contact tracing infrastructure to develop, test, and evaluate a culturally- responsive SARS-CoV-2 testing intervention, collection of additional data on COVID-19 related health disparities, and identification of additional attitudes, facilitators, and barriers to testing and eventual vaccination. The investigators have designed an approach that not only allows for collecting essential information about community, provider, and patient-relevant impediments to viral testing but also meeting the critical need to increase testing in testing deserts in Oklahoma as rapidly as possible. The investigators believe that a singular focus on one testing strategy will be ineffective in truly understanding the barriers to testing. No one strategy would be effective in reaching all of the population, due to issues such as lack of access to a primary care provider, lack of insurance, transportation, available time, or individual/community perceptions on testing itself (e.g., safety, necessity, availability, trust). Thus, the investigators have chosen to develop the Community-engaged Approaches to Testing in Community and Healthcare settings for Underserved Populations (CATCH-UP) program with practice-based and community-based approaches to maximize the reach of the RADx-UP consortium, broaden the potential perspectives that could be captured, and compare the effectiveness of strategies. Rather than developing an inflexible practice-based intervention a priori, the investigators believe that the ever-changing barriers, attitudes and conditions in the pandemic, as well as the development and deployment of more effective diagnostic technologies over the next few months, necessitate a pragmatic approach in which increased testing is initiated quickly while simultaneously collaborating with stakeholders and collecting participant survey data in real-time, which will allow the intervention to evolve to changing needs, and provide rapid-cycle evaluation of effectiveness of these activities to provide timely feedback to the partners and other RADx-UP initiatives. The specific aims of the CATCH-UP Project are as follows: 1. Provide technical support to a minimum of 50 Oklahoma primary care practices to implement a person-centered approach to SARS-CoV-2 testing based on best available evidence and current guidelines. The implementation approach will include 1) development of implementation support resources for COVID-19 testing and risk mitigation strategies to meet the needs of vulnerable populations through continuous adaption to changing guidelines, testing protocols and availability, and information learned from the project's provider network and the broader RADx-UP community, 2) support practices to integrate tailored, guideline- based SARS-CoV-2 testing protocols and resources into the workflows through proven methodologies of academic detailing from peer-physician experts, practice change facilitation through quality improvement implementation professionals, and health information technology support. Based on the average number of providers and daily caseload in rural Oklahoma practices the investigators estimate this will result in approximately 60,000 viral tests performed in the first year. 2. Rapidly respond to community testing needs by deploying mobile testing units in community settings that will provide operational support to increase the efficiency and the existing capacity for statewide testing by Oklahoma's public health authorities. The model used by the Chickasaw Nation in deploying a high-efficiency community testing system will be combined with ongoing observation and analysis to identify facilitators and barriers to implementing community testing sites to accelerate convergence on effective and replicable methods to increase access and acceptance of testing. The investigators will adapt to ongoing disease outbreaks and community needs, but anticipate that this aim will result in more than 250 testing events at sites throughout the state and 45,000 viral tests performed in the first year. 3. Conduct a comprehensive evaluation of the impact of the CATCH-UP program, collaborate closely with other RADx-UP projects in sharing data and adapting processes, and continuously communicate with our community partners to assess effectiveness and disseminate research findings. This evaluation will include measurement and dissemination of data related to 1) Provider-level Outcomes that include knowledge and attitudes of disease prevalence, clinical characteristics including typical and atypical symptoms and disease severity, testing importance and strategies, vaccination, importance and use of personal protective equipment, availability of testing and delays in return of results, and provider observations of patient attitudes and other reported barriers, 2) Care Process Outcomes such as testing, test positivity, and test refusal rates, influenza, pneumococcal, and zoster vaccination rates, 3) Community-level Outcomes that include the number of tests conducted by mobile testing units and the resulting test positivity rate, 4) Patient-level Outcomes such as knowledge and attitudes of disease prevalence, disease characteristics including severity and acute and chronic symptoms, risk perspective and preferences, importance and use of personal protective equipment, patient acceptance of various testing options, and facilitators and barriers to participating in testing and future vaccination programs, 5) Patient Factors such as demographics, social determinants of health, and clinical characteristics that may be associated with COVID-19 morbidity and mortality disparities or reach of each testing modality, and 6) Qualitative Outcomes including perceptions of facilitators and barriers to testing and the utility, effectiveness, and generalizability of the program, explored through key informant interviews, exit interviews, and in-depth program implementation process observations.

Interventions

Dissemination and Implementation research involves assisting primary care practices to address SARS-CoV-2 testing using evidence-based practices as well as increased testing in mobile-based community settings. The D&I model also involves Practice Assessment, Academic Detailing, Practice Facilitation, Health Information Technology Support, Performance Feedback and Benchmarking, and a Virtual Learning Community.

Sponsors

National Institutes of Health (NIH)
CollaboratorNIH
National Institute of General Medical Sciences (NIGMS)
CollaboratorNIH
University of Oklahoma
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Intervention model description

Dissemination and Implementation Research (D&I): Involves assisting primary care practices to address SARS-CoV-2 testing using evidence-based practices as well as increased testing in mobile-based community settings. The D&I model also involves Practice Assessment, Academic Detailing, Practice Facilitation, Health Information Technology Support, Performance Feedback and Benchmarking, and a Virtual Learning Community.

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* Practices: 1. Primary care practices located in Oklahoma. 2. Priority to practices serving a majority of patients that are underserved or vulnerable populations (rural, minority, elderly). 3. Practices routinely using a certified electronic health record (EHR) will be eligible to participate, as practices that are still using paper records are either planning to close due to clinician retirement or will likely be implementing an EHR during the project, which would compromise their ability to participate. 4. Practice-wide participation will be encouraged, but participation of all members within a practice (both clinicians and staff members) will not be required. The minimum acceptable level of participation will be one clinician and nurse/medical assistant dyad plus anyone else who would have to be involved to make changes in the processes of care (e.g. clinic manager) for that unit of care. 5. Clinicians and staff members 18 years of age and older at the time of enrollment (consent). * Patients survey participants: 1. Patients (or caregivers of patients) who are seen in eligible practices or community testing sites and received a recommendation for the patient to receive a SARS-CoV-2 diagnostic test. 2. Patients (or their caregivers) who are 18 or older

Exclusion criteria

* Practices: 1. Practices that are uninterested in reducing missed opportunities for guidelines-based testing for SARS-CoV-2 2. Solo practices with a clinician planning to retire within 12 months of enrollment will not be eligible for participation. 3. Practices likely to experience ownership change in the next 12 months will not be eligible for participation. * Patient survey participants: 1. Patients unable to complete the consent process or survey instruments in English or Spanish. 2. Patients or caregivers of patients who are under the age of 18.

Design outcomes

Primary

MeasureTime frameDescription
Barriers to SARS-CoV-2 Testing (Practices)Month 3Number (and type) of barriers to SARS-CoV-2 testing reported by practice members based on what they experienced during practice encounters with patients during the study.
Change in SARS-CoV-2 Testing Rate (Practices)Baseline to 12 monthsChange in the proportion of patients eligible for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) testing based on screening that receive SARS-CoV-2 test. The proportion ranges between zero and one.
Change in SARS-CoV-2 Test Positivity RateBaseline to 12 monthsChange in the proportion of SARS-CoV-2 test results that are positive.
Barriers to SARS-CoV-2 TestingBaselineNumber (and type) of barriers to SARS-CoV-2 testing reported by practice members based on what they experienced during practice encounters with patients during the study.

Secondary

MeasureTime frameDescription
Change in Influenza Vaccination Rate (NQF #41)Baseline to 12 monthsChange in the proportion of patients aged 6 months and older who received an influenza immunization or reported receipt of an influenza immunization. Influenza Vaccination Rate was defined in alignment with National Quality Forum (NQF) measure #41 and was recorded as a proportion ranging between zero and one.
Change in Pneumococcal Vaccination Rate (NQF #127)Baseline to 12 monthsChange in the proportion of patients 65 years of age or older who have ever received a pneumococcal vaccine. Pneumococcal Vaccination Rate was defined in alignment with National Quality Forum (NQF) measure #41 and was recorded as a proportion ranging between zero and one.
Change in Zoster Vaccination RateBaseline to 12 monthsChange in the proportion of patients aged 50 years and older who have had the Shingrix zoster (shingles) vaccination. Proportion ranges from zero to one.
COVID-19 ReferralsBaselinePractices that reported not administering the COVID-19 vaccine were asked Where do you send your patients that require a COVID-19 vaccine? on the Practice Member Survey.

Countries

United States

Participant flow

Participants by arm

ArmCount
Primary Care Practices
A practice-based implementation study was conducted with 35 practices, with baseline data collection, and overlapping with interim measurements of care quality and process outcomes, followed by a final data collection at the end of the intervention (including baseline measures plus semi-structured interviews. The practice based approach to increasing testing will be compared to a community-based approach using mobile-setting to increase testing. Additional, non-clinical trial components of this study include patient surveys to understand facilitators and barriers to SARS-CoV-2 testing and identification of legal/ethical, socioeconomic, and behavioral implications of increased testing. Patients are not direct subjects in this part of the study. Intervention will target practices and practice members. Dissemination and Implementation Research: Dissemination and Implementation research involves assisting primary care practices to address SARS-CoV-2 testing using evidence-based practices as well as increased testing in mobile-based community settings. The D&I model also involves Practice Assessment, Academic Detailing, Practice Facilitation, Health Information Technology Support, Performance Feedback and Benchmarking, and a Virtual Learning Community.
323
Primary Care Practices
A practice-based implementation study was conducted with 35 practices, with baseline data collection, and overlapping with interim measurements of care quality and process outcomes, followed by a final data collection at the end of the intervention (including baseline measures plus semi-structured interviews. The practice based approach to increasing testing will be compared to a community-based approach using mobile-setting to increase testing. Additional, non-clinical trial components of this study include patient surveys to understand facilitators and barriers to SARS-CoV-2 testing and identification of legal/ethical, socioeconomic, and behavioral implications of increased testing. Patients are not direct subjects in this part of the study. Intervention will target practices and practice members. Dissemination and Implementation Research: Dissemination and Implementation research involves assisting primary care practices to address SARS-CoV-2 testing using evidence-based practices as well as increased testing in mobile-based community settings. The D&I model also involves Practice Assessment, Academic Detailing, Practice Facilitation, Health Information Technology Support, Performance Feedback and Benchmarking, and a Virtual Learning Community.
35
Total358

Baseline characteristics

CharacteristicPrimary Care Practices
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
11 Participants
Age, Categorical
Between 18 and 65 years
168 Participants
Race (NIH/OMB)
American Indian or Alaska Native
13 Participants
Race (NIH/OMB)
Asian
2 Participants
Race (NIH/OMB)
Black or African American
9 Participants
Race (NIH/OMB)
More than one race
23 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
125 Participants
Race (NIH/OMB)
White
151 Participants
Region of Enrollment
United States
323 participants
Sex: Female, Male
Female
172 Participants
Sex: Female, Male
Male
23 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
2 / 323
other
Total, other adverse events
0 / 323
serious
Total, serious adverse events
0 / 323

Outcome results

Primary

Barriers to SARS-CoV-2 Testing

Number (and type) of barriers to SARS-CoV-2 testing reported by practice members based on what they experienced during practice encounters with patients during the study.

Time frame: Baseline

Population: Primary care practice members reported barriers to SARS-CoV-2 testing on a Practice Member Survey. Practice members could report more than one barrier.

ArmMeasureGroupValue (NUMBER)
Primary Care PracticesBarriers to SARS-CoV-2 TestingNot feeling sick therefore not wanting to be tested134 participants
Primary Care PracticesBarriers to SARS-CoV-2 TestingTesting not available41 participants
Primary Care PracticesBarriers to SARS-CoV-2 TestingNot knowing where to go for testing87 participants
Primary Care PracticesBarriers to SARS-CoV-2 TestingChildcare67 participants
Primary Care PracticesBarriers to SARS-CoV-2 TestingNot able to take time off work116 participants
Primary Care PracticesBarriers to SARS-CoV-2 TestingFear of receiving nasopharyngeal testing119 participants
Primary Care PracticesBarriers to SARS-CoV-2 TestingTransportation69 participants
Primary Care PracticesBarriers to SARS-CoV-2 TestingNot being able to pay95 participants
Primary

Barriers to SARS-CoV-2 Testing (Practices)

Number (and type) of barriers to SARS-CoV-2 testing reported by practice members based on what they experienced during practice encounters with patients during the study.

Time frame: Month 3

Population: Primary care practice members reported barriers to SARS-CoV-2 testing on a Practice Member Survey. Practice members could report more than one barrier.

ArmMeasureGroupValue (NUMBER)
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Not feeling sick therefore not wanting to be tested62 participants
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Testing not available3 participants
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Fear of receiving nasopharyngeal testing58 participants
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Transportation27 participants
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Not being able to pay27 participants
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Not knowing where to go for testing22 participants
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Childcare19 participants
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Not able to take time off work45 participants
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Already had COVID-19 and don't think testing is needed58 participants
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Don't see testing as important29 participants
Primary

Barriers to SARS-CoV-2 Testing (Practices)

Number (and type) of barriers to SARS-CoV-2 testing reported by practice members based on what they experienced during practice encounters with patients during the study.

Time frame: Month 9

Population: Primary care practice members reported barriers to SARS-CoV-2 testing on a Practice Member Survey. Practice members could report more than one barrier.

ArmMeasureGroupValue (NUMBER)
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Not feeling sick therefore not wanting to be tested60 participants
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Testing not available7 participants
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Fear of receiving nasopharyngeal testing45 participants
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Transportation27 participants
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Not being able to pay21 participants
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Not knowing where to go for testing12 participants
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Childcare27 participants
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Not able to take time off work42 participants
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Already had COVID-19 and don't think testing is needed68 participants
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Don't see testing as important43 participants
Primary

Barriers to SARS-CoV-2 Testing (Practices)

Number (and type) of barriers to SARS-CoV-2 testing reported by practice members based on what they experienced during practice encounters with patients during the study.

Time frame: Month 12

Population: Primary care practice members reported barriers to SARS-CoV-2 testing on a Practice Member Survey. Practice members could report more than one barrier.

ArmMeasureGroupValue (NUMBER)
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Childcare25 participants
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Not feeling sick therefore not wanting to be tested48 participants
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Testing not available3 participants
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Fear of receiving nasopharyngeal testing39 participants
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Transportation24 participants
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Not being able to pay16 participants
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Not knowing where to go for testing9 participants
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Not able to take time off work48 participants
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Already had COVID-19 and don't think testing is needed56 participants
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Don't see testing as important39 participants
Primary

Barriers to SARS-CoV-2 Testing (Practices)

Number (and type) of barriers to SARS-CoV-2 testing reported by practice members based on what they experienced during practice encounters with patients during the study.

Time frame: Month 6

Population: Primary care practice members reported barriers to SARS-CoV-2 testing on a Practice Member Survey. Practice members could report more than one barrier.

ArmMeasureGroupValue (NUMBER)
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Don't see testing as important34 participants
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Not feeling sick therefore not wanting to be tested59 participants
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Testing not available5 participants
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Fear of receiving nasopharyngeal testing45 participants
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Transportation23 participants
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Not being able to pay28 participants
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Not knowing where to go for testing17 participants
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Childcare25 participants
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Not able to take time off work45 participants
Primary Care PracticesBarriers to SARS-CoV-2 Testing (Practices)Already had COVID-19 and don't think testing is needed63 participants
Primary

Change in SARS-CoV-2 Testing Rate (Practices)

Change in the proportion of patients eligible for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) testing based on screening that receive SARS-CoV-2 test. The proportion ranges between zero and one.

Time frame: Baseline to 12 months

Population: The average proportion of patients receiving a SARS-CoV-2 test at the practice-level. Data were collected at the practice level only, no participant or patient level data were collected.

ArmMeasureGroupValue (MEAN)Dispersion
Primary Care PracticesChange in SARS-CoV-2 Testing Rate (Practices)Baseline0.9928 proportion of patients (ranging 0-1)Standard Deviation 0.0348
Primary Care PracticesChange in SARS-CoV-2 Testing Rate (Practices)12 months1 proportion of patients (ranging 0-1)Standard Deviation 0
Primary

Change in SARS-CoV-2 Test Positivity Rate

Change in the proportion of SARS-CoV-2 test results that are positive.

Time frame: Baseline to 12 months

Population: The proportion of SARS-CoV-2 tests conducted at each participating practice that were positive were recorded at both baseline and at 12 months. These practice-level proportions were averaged. Data were collected at the practice level only, no participant or patient level data were collected.

ArmMeasureGroupValue (MEAN)Dispersion
Primary Care PracticesChange in SARS-CoV-2 Test Positivity Rate12 Months0.2545 proportion of tests (ranging 0-1)Standard Deviation 0.1862
Primary Care PracticesChange in SARS-CoV-2 Test Positivity RateBaseline0.0660 proportion of tests (ranging 0-1)Standard Deviation 0.0972
Secondary

Change in Influenza Vaccination Rate (NQF #41)

Change in the proportion of patients aged 6 months and older who received an influenza immunization or reported receipt of an influenza immunization. Influenza Vaccination Rate was defined in alignment with National Quality Forum (NQF) measure #41 and was recorded as a proportion ranging between zero and one.

Time frame: Baseline to 12 months

Population: Proportion of patients receiving influenza vaccine at the practice-level at baseline versus at 12 months. Data were collected at the practice level only, no participant or patient level data were collected.

ArmMeasureGroupValue (MEAN)Dispersion
Primary Care PracticesChange in Influenza Vaccination Rate (NQF #41)12 Months0.1110 proportion of patients (ranging 0-1)Standard Deviation 0.1701
Primary Care PracticesChange in Influenza Vaccination Rate (NQF #41)Baseline0.2376 proportion of patients (ranging 0-1)Standard Deviation 0.2051
Secondary

Change in Pneumococcal Vaccination Rate (NQF #127)

Change in the proportion of patients 65 years of age or older who have ever received a pneumococcal vaccine. Pneumococcal Vaccination Rate was defined in alignment with National Quality Forum (NQF) measure #41 and was recorded as a proportion ranging between zero and one.

Time frame: Baseline to 12 months

Population: Proportion of patients receiving pneumococcal vaccine at the practice-level at baseline versus at 12 months. Data were collected at the practice level only, no participant or patient level data were collected.

ArmMeasureGroupValue (MEAN)Dispersion
Primary Care PracticesChange in Pneumococcal Vaccination Rate (NQF #127)Baseline0.1240 proportion of patients (ranging 0-1)Standard Deviation 0.1749
Primary Care PracticesChange in Pneumococcal Vaccination Rate (NQF #127)12 Months0.1053 proportion of patients (ranging 0-1)Standard Deviation 0.1805
Secondary

Change in Zoster Vaccination Rate

Change in the proportion of patients aged 50 years and older who have had the Shingrix zoster (shingles) vaccination. Proportion ranges from zero to one.

Time frame: Baseline to 12 months

Population: Data were not collected because collection of Zoster vaccination rates from primary care practices requires an electronic medical record query that was not available across participating practices.

Secondary

COVID-19 Referrals

Practices that reported not administering the COVID-19 vaccine were asked Where do you send your patients that require a COVID-19 vaccine? on the Practice Member Survey.

Time frame: Baseline

Population: The plan was to report where primary care practices reported referring patients to for the COVID-19 vaccine, but data were not collected for this time frame.

Secondary

COVID-19 Referrals

Practices that reported not administering the COVID-19 vaccine were asked Where do you send your patients that require a COVID-19 vaccine? on the Practice Member Survey.

Time frame: Month 3

Population: The plan was to report where primary care practices reported referring patients to for the COVID-19 vaccine, but data were not collected for this time frame.

Secondary

COVID-19 Referrals

Practices that reported not administering the COVID-19 vaccine were asked Where do you send your patients that require a COVID-19 vaccine? on the Practice Member Survey.

Time frame: Month 6

Population: Primary care practice members reported where they refer patients to for the COVID-19 vaccine. Note, practice members could report more than one referral location.

ArmMeasureGroupValue (NUMBER)
Primary Care PracticesCOVID-19 ReferralsLocal health department51 participants
Primary Care PracticesCOVID-19 ReferralsPharmacy50 participants
Primary Care PracticesCOVID-19 ReferralsOther provider in health system10 participants
Primary Care PracticesCOVID-19 ReferralsOther5 participants
Secondary

COVID-19 Referrals

Practices that reported not administering the COVID-19 vaccine were asked Where do you send your patients that require a COVID-19 vaccine? on the Practice Member Survey.

Time frame: Month 9

Population: Primary care practice members reported where they refer patients to for the COVID-19 vaccine. Note, practice members could report more than one referral location.

ArmMeasureGroupValue (NUMBER)
Primary Care PracticesCOVID-19 ReferralsLocal health department56 participants
Primary Care PracticesCOVID-19 ReferralsPharmacy56 participants
Primary Care PracticesCOVID-19 ReferralsOther provider in health system7 participants
Primary Care PracticesCOVID-19 ReferralsOther2 participants
Secondary

COVID-19 Referrals

Practices that reported not administering the COVID-19 vaccine were asked Where do you send your patients that require a COVID-19 vaccine? on the Practice Member Survey.

Time frame: Month 12

Population: Primary care practice members reported where they refer patients to for the COVID-19 vaccine. Note, practice members could report more than one referral location.

ArmMeasureGroupValue (NUMBER)
Primary Care PracticesCOVID-19 ReferralsLocal health department46 participants
Primary Care PracticesCOVID-19 ReferralsPharmacy36 participants
Primary Care PracticesCOVID-19 ReferralsOther provider in health system5 participants
Primary Care PracticesCOVID-19 ReferralsOther1 participants

Source: ClinicalTrials.gov · Data processed: May 11, 2026